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Abstract
Background: Assessing the risk of bias in individual studies in a systematic review can be done
using individual components or by summarizing the study quality in an overall score.
Methods: We examined the instructions to authors of the 50 Cochrane Review Groups that focus
on clinical interventions for recommendations on methodological quality assessment of studies.
Results:  Forty-one of the review groups (82%) recommended quality assessment using
components and nine using a scale. All groups recommending components recommended to assess
concealment of allocation, compared to only two of the groups recommending scales (P < 0.0001).
Thirty-five groups (70%) recommended assessment of sequence generation and 21 groups (42%)
recommended assessment of intention-to-treat analysis. Only 28 groups (56%) had specific
recommendations for using the quality assessment of studies analytically in reviews, with sensitivity
analysis, quality as an inclusion threshold and subgroup analysis being the most commonly
recommended methods. The scales recommended had problems in the individual items and some
of the groups recommending components recommended items not related to bias in their quality
assessment.
Conclusion: We found that recommendations by some groups were not based on empirical
evidence and many groups had no recommendations on how to use the quality assessment in
reviews. We suggest that all Cochrane Review Groups refer to the Cochrane Handbook for
Systematic Reviews of Interventions, which is evidence-based, in their instructions to authors and
that their own guidelines are kept to a minimum and describe only how methodological topics that
are specific to their fields should be handled.
Background
The strength of systematic reviews of randomized trials
and observational studies, as opposed to narrative reviews
and expert opinion, is the application of systematic strat-
egies to reduce bias. Since the conclusion may become
unreliable if the data are flawed, this involves an assess-
ment of the internal validity of the included studies [1].
The term methodological quality is often used instead of
internal validity, but as quality may address issues that are
not related to bias, it would be preferable to speak about
an assessment of the risk of bias.
There are four main areas of bias in controlled clinical
studies: selection bias (differences in baseline characteris-
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tics between the groups of prognostic importance), per-
formance bias (unequal provision of care apart from the
treatment under evaluation), detection bias (biased out-
come assessment) and attrition bias (biased occurrence
and handling of deviations from the protocol and loss to
follow-up) [2-8].
The outcome of the risk-of-bias assessment can be listed
for the different methodological areas separately (compo-
nent approach) or by summarizing the information in an
overall quality score (scale approach). The risk-of-bias
assessment can be used in the review with a variety of
approaches. For example, as a threshold for inclusion of
studies; as a possible explanation for differences in results
between subgroups of studies; by performing sensitivity
analyses where only some of the studies are included; or
by using a risk-of-bias score as a weight in a meta-analysis
of the results.
Using a scale can be tempting but is not well supported by
empirical research [9-11]. A major problem with scales is
that they often incorporate items that are more related to
the quality of reporting, ethical issues or statistical issues
than to bias [11].
The biggest producer of systematic reviews, the Cochrane
Collaboration, advises against the use of scales [12]. After
peer review, the reviews are edited by one of the 51
Cochrane Review Groups related to different fields of
healthcare. Most review groups have their own set of
instructions to authors, based on the Cochrane Hand-
book for Systematic Reviews of Interventions [12], and
these guidelines are published in the Cochrane Library
under the description of the Cochrane Collaboration [13].
There are currently more than 3,000 Cochrane reviews
and they have been shown to be of higher methodological
quality, on average, than other systematic reviews [14,15].
However, a previous study of 809 Cochrane reviews pub-
lished from 1995 to 2002 reported that 36% of the review
authors had used scales [16]. We examined how the differ-
ent review groups currently recommend assessment and
handling of the risk of bias in the studies, with a focus on
the use of scales, and suggest possible improvements.
Methods
We reviewed the guidelines for assessment of methodo-
logical quality of the primary studies included in
Cochrane reviews. In March 2007, one author (A.L.)
extracted the relevant data from the descriptions of the
Cochrane Review Groups in the Cochrane Library, supple-
mented with information from websites when reference
was made to such sites, and with contacts to the review
groups to clarify any uncertainties. The other author
(P.C.G.) checked the extracted data, and any disagree-
ments were resolved by discussion. Of the 51 review
groups, we excluded the Methodology Review Group, as
these reviews do not address clinical interventions.
A standardised data sheet was used and data were
extracted on:
1) The type of methodological quality assessment recom-
mended for individual studies, i.e. a component or a scale
approach.
2) Areas of methodological quality and other areas recom-
mended to be assessed.
3) Recommendations for using methodological quality
assessments of individual studies in reviews, e.g. for inclu-
sion of studies or for analytic purposes.
4) Recommendations to grade the level of evidence for the
review as a whole.
Six review groups were asked for clarifications and all
replied. The Upper Gastrointestinal and Pancreatic Dis-
eases Group was unable to address our questions because
it was being reorganized.
Groups that did not provide any recommendations, but
referred to the Cochrane Handbook, were classified as rec-
ommending a component approach, since the Handbook
advises that quality scores should not be used (as this
approach is not supported by empirical research, can be
time-consuming, and is potentially misleading) [12].
These groups were regarded as having addressed the main
areas of bias mentioned in the Handbook: generation of
allocation sequence; concealment of allocation; blinding
of patients, caregivers and outcome assessors; and follow-
up. They were also classified as giving no specific advice
for using methodological quality assessments of individ-
ual studies in reviews, as the Handbook has no specific
recommendations on this. Groups that offered no infor-
mation and no reference to the Handbook were treated
similarly, as we regarded referral to the Handbook as
implicit in these cases. Groups that recommended both
scales and components as optional were classified as rec-
ommending scales (there were only two such groups).
Groups that recommended checklists of individual items
were classified as recommending components, unless an
overall score was calculated. Finally, for groups that rec-
ommended specific items in their guidelines but also
referred to the Handbook, we assessed what they recom-
mended in their guidelines.
We report the number of groups that recommended scales
or components, areas of methodological quality assessed,
specific recommendations for using the assessments ofBMC Medical Research Methodology 2008, 8:22 http://www.biomedcentral.com/1471-2288/8/22
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individual studies in the reviews, and type of analytical
approach recommended, e.g. subgroup or sensitivity anal-
yses, or meta-regression. We used Fisher's exact test to
compare proportions [17].
Results
Scales and components
Forty-one of the 50 review groups (82%) recommended a
component approach, 34 of these explicitly, including 16
which also had reservations about scales (Table 1).
Twenty-three of these 41 groups had their own checklists,
ranging from 4 to 23 items.
The remaining nine groups (18%) recommended a scale
approach (two as optional to a component approach).
Five groups explicitly recommended the Jadad scale, one
used it in their model review, one recommended it as
optional to a component approach, one recommended
different options of checklists and scales that included the
Jadad scale, and one explicitly recommended an 11-item
checklist used as a scale.
Most review groups recommended assessing the genera-
tion of the randomization sequence (70%), concealment
of allocation (86%), blinding of patients (84%), caregiv-
ers (66%) and outcome assessors (96%), and follow-up
(94%) (Table 2). However, only two of the nine groups
that recommended scales advised authors to consider
concealment of allocation, compared with all 41 groups
that recommended components (P < 0.0001). In contrast,
all nine groups recommending scales recommended
assessment of sequence generation compared to 26 out of
41 groups recommending components (P = 0.04). Fur-
thermore, only one of the groups that recommended
scales advised to assess whether the trial authors had con-
ducted an intention-to-treat analysis, compared to 20
groups that recommended components (P = 0.06).
Four groups (one that recommended scales and three that
recommended components) used limits for loss to fol-
low-up (ranging from 10% to 30%) to judge whether
attrition bias was avoided. Two review groups regarded
blinding as insufficient if the treatment could be identi-
fied in more than 20% of the patients because of side
effects.
One group, the Back Group, that recommended a scale
approach had included items that are not necessarily
related to risk of bias in their scale, e.g. similarities
between groups at baseline, use of co-intervention, com-
pliance and timing of outcome assessment.
Content of checklists
The items included in the checklists used by some groups
addressed methodological quality, external validity (e.g.
inclusion criteria, diagnostic criteria, precision of diagnos-
tic tool, clinical usefulness of the outcome assessment
tool, and duration of study), harms (e.g. details of side
effects) and statistics (e.g. sample size, power calculation,
presentation of the results and appropriateness of the
analysis). Four of the 23 checklists contained an assess-
ment of comparability at baseline.
Twenty-eight groups (56%) recommended authors to use
the methodological quality assessment of the individual
studies in the analyses, one group recommended their use
only for descriptive purposes, and the remaining 21
groups gave no recommendations (Table 3). Eight of the
nine groups (89%) that recommended scales advised an
analytical usage of the assessments, compared to only 20
of the 41 groups (49%) that recommended components
(P = 0.06). Twenty-four groups (86%) that recommended
an analytical approach advised sensitivity analyses. In
addition, seven also recommended the authors to use the
methodological quality as a threshold for inclusion of tri-
als and seven recommended subgroup analyses compar-
ing high- and low-quality trials. Six groups recommended
Table 1: Type of methodological quality assessment recommended to be used by Cochrane Review Groups. Values are numbers 
(percentages)
Type Recommended (n = 50)
Component 41 (82)
Component explicitly recommended, reservations towards scales 16 (32)
Component explicitly recommended 18 (36)
Component recommended through quotation of Cochrane Handbook 3 (6)
Component assumed recommended as there was no information 4 (8)
Scale 9 (18)
Scale explicitly recommended 7 (14)
Scale optional 2 (4)BMC Medical Research Methodology 2008, 8:22 http://www.biomedcentral.com/1471-2288/8/22
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to use the quality in a cumulative meta-analysis, as a
weight in the meta-analysis, or in meta-regression (Table
4).
Grading the level of evidence
Two groups graded the evidence for the review as a whole.
The Back Group recommended using five levels of evi-
dence (no, conflicting, limited, moderate and strong evi-
dence) for qualitative reviews, where data were
impossible or too heterogeneous to pool, based on study
design and overall study quality. The Musculoskeletal
Group recommended four levels of evidence for both
qualitative and quantitative reviews based on study
design, specific areas of methodological quality and sam-
ple size (bronze, silver, gold and platinum).
Discussion
Scales
We found that 18% of the Cochrane review groups recom-
mended scales for the methodological quality assessment
without any reservations. Our study could suggest that
scales may now be used less often, but our results are not
directly comparable to those of Moja et al. who found that
36% of the review authors of reviews published from
1995 to 2002 had used scales and that the Jadad scale was
most frequently used [16]. Authors may decide to use a
component approach although the group recommends a
scale, or vice versa, and the numbers of reviews produced
are not equally distributed among groups. Even so, we
believe the guidelines of the groups are important.
Cochrane Reviews are undertaken by authors with differ-
ent levels of methodological training, and guidelines are
probably followed more strictly by less experienced
authors. This can be problematic if the guidelines are not
in accordance with the empirical research on bias.
The Jadad scale is the only scale that has been developed
using established standards for scales and where low
scores have been associated with increased effect estimates
[5,9,18,19]. It consists of three items, and up to two
points are given for randomization, two for double blind-
ing and one for withdrawals and dropouts (Figure 1). An
overall score between zero and five is assigned, where
three is commonly regarded as adequate trial quality [18].
Despite its thorough development and validation, the
scale is problematic. First, it has more focus on the quality
of reporting than on methodological quality [7,8,11]. Sec-
ond, for randomization, the scale addresses explicitly the
sequence generation but not concealment of allocation.
The guidelines for the scale state that the investigators
should not be able to predict which treatment was next,
but this is an implicit way of describing concealment of
allocation that may easily be overlooked by the assessors.
It is generally considered that the scale does not address
this domain [7,8,11]. Third, the scale does not address
blinding of caregivers or intention-to-treat analysis. There-
fore, randomized trials with no concealment of alloca-
tion, no blinding, with large numbers of dropouts that are
well described, and with only a per-protocol analysis, may
be scored as of good methodological quality (three
points). Fourth, studies have shown low interrater agree-
ment, particularly for withdrawals and dropouts, where
kappa values below zero have been reported [20,21],
which is an agreement that is worse than that expected by
chance. Fifth, the Jadad scale – and many other scales –
punishes research areas where blinding may be neither
Table 2: Areas of methodological quality recommended to be assessed in reviews by Cochrane Review Groups. Values are numbers 
(percentages)
Area of quality recommended All (n = 50) Components (n = 41) Scales (n = 9)
Sequence generation 35 (70) 26 (63) 9 (100)
Concealment of allocation 43 (86) 41 (100) 2 (22)
Blinding of patients 42 (84) 33 (80) 9 (100)
Blinding of caregivers 33 (66) 32 (78) 1 (11)
Blinding of outcome assessors 48 (96) 39 (95) 9 (100)
Follow-up 47 (94) 38 (93) 9 (100)
Intention-to-treat analysis 21 (42) 20 (49) 1 (11)
Table 3: Recommendations by Cochrane Review Groups for using quality assessments of individual studies in reviews. Values are 
numbers (percentages)
Approach recommended All (n = 50) Components (n = 41) Scales (n = 9)
Analytical approach 28 (56) 20 (49) 8 (89)
Descriptive approach 1 (2) 1 (2) 0 (0)
No information 21 (42) 20 (49) 1 (11)BMC Medical Research Methodology 2008, 8:22 http://www.biomedcentral.com/1471-2288/8/22
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feasible, nor relevant, e.g. trials in cancer surgery with total
mortality as the main outcome.
Despite advising against scales, the Cochrane Handbook
actually recommends a ranking scale [12]. The scale dis-
tinguishes between low risk of bias (all criteria met), mod-
erate risk of bias (one or more criteria partly met) and
high risk of bias (one or more criteria not met). The types
of criteria are not specified, other than they should be few
and address substantive threats to the validity of the study
results. This scale was recommended explicitly by two
groups and implicitly by seven others. In one place, the
Handbook states that authors or review groups can use a
scale, but that it must be with caution. This is in contrast
to the general advice against scales, and this ambiguity can
perhaps explain why some groups recommend scales.
Table 4: Type of analytical approach recommended to be used in reviews by Cochrane Review Groups. Values are numbers 
(percentages)
Type of analytical approach* All (n = 28) Components (n = 20) Scales (n = 8)
Sensitivity analysis 24 (86) 17 (85) 7 (88)
Threshold 7 (25) 4 (20) 3 (38)
Subgroup analysis 7 (25) 4 (20) 3 (38)
Cumulative analysis 3 (11) 1 (5) 2 (25)
Weights 2 (7) 1 (5) 1 (13)
Meta-regression 1 (4) 0 (0) 1 (13)
* More than one answer possible
The Jadad scale Figure 1
The Jadad scale.
1. Was the study described as randomized (this includes the use of words such as randomly, random, and randomization)?
2. Was the study described as double blind?
3. Was there a description of withdrawals and dropouts?
Scoring the items:
Either give a score of 1 point for each “yes” or 0 points for each “no”. There are no in-between marks.
Give 1 additional point if: For question 1 the method to generate the sequence of randomisation was described and it was
appropriate (table of random numbers, computer generated, coin tossing, etc).
and / or: If for question 2 the method of double-blinding was described and it was appropriate
(identical placebo, active placebo, dummy, etc).
Deduct 1 point if: For question 1 the method to generate the sequence of randomisation was described and it was
inappropriate (patients were allocated alternately, or according to date of birth, hospital
number, etc).
and / or: For question 2 the study was described as double-blind but the method of blinding was
inappropriate (e.g., comparison of tablet vs. injection with no double dummy).
Guidelines for Assessment
1. Randomisation
A method to generate the sequence of randomisation will be regarded as appropriate if it allowed each study participant to have the same
chance of receiving each intervention and the investigators could not predict which treatment was next. Methods of allocation using date of
birth, date of admission, hospital numbers or alternation should not be regarded as appropriate.
2. Double-blinding
A study must be regarded as double-blind if the word double-blind is used. The method will be regarded as appropriate if it is stated that
neither the person doing the assessments nor the study participant could identify the intervention being assessed, or if in the absence of such
a statement, the use of active placebos, identical placebos or dummies is mentioned.
3. Withdrawals and drop outs
Participants who were included in the study but did not complete the observation period or who were not included in the analysis must be
described. The number and the reasons for withdrawal must be stated. If there were no withdrawals, it should be stated in the article. If
there is no statement on withdrawals, this item must be given no points.BMC Medical Research Methodology 2008, 8:22 http://www.biomedcentral.com/1471-2288/8/22
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The weights and the direction of the bias for the individ-
ual items is a substantial problem with scales. As pointed
out by Greenland, a true association with two or more
components may be overlooked if the associations cancel
out in the total score, or if these components have so little
weight that this variation is lost in the total score [22].
Usually, all items are given the same weight although it is
clear that they do not contribute equally to avoiding bias.
For example, the Back Group uses a scale with 11 items,
and trials of acceptable quality are defined as those meet-
ing 50% of the criteria (i.e. a minimum of six) [23]. Thus,
items on compliance, distribution of co-interventions and
timing of outcome assessment are given the same weight
as concealment of allocation, which, along with blinding,
has been documented as the most important safeguard
against bias [3,4]. With this scale, trials that have no con-
cealment of allocation and no blinding can be judged to
be of acceptable quality.
The many problems with scales are illustrated in a study
by Jüni et al. [11]. These authors used 25 existing scales to
identify high-quality trials, and found that the effect esti-
mates and conclusions of the same meta-analysis varied
substantially with the scale used.
Sequence generation
About two-thirds of groups recommended assessing
sequence generation. This could be an improvement from
the 26% reported previously for Cochrane Reviews [16].
Adequate concealment of allocation may not prevent
against selection bias if the sequence generation is deci-
phered by the persons enrolling patients [4,5,7,24].
Intention-to-treat analyses
Per-protocol analyses will often lead to substantial overes-
timation of treatment effects [25-27]. The Cochrane
Handbook recommends analyzing all data according to
the intention-to-treat principle using different analytical
methods such as imputation. Currently it has no recom-
mendations for assessing intention-to-treat analysis as a
methodological item or how to assess attrition bias (i.e.
loss to follow-up). This is in contrast with 21 groups that
recommend to assess intention-to-treat as a separate item
using different criteria. While large numbers of loss to fol-
low-up have been associated with bias [6], the use of arbi-
trarily defined cut-points from 10–30% for assessing
attrition bias is not based on empirical results and should
therefore not be part of instructions to authors. These
findings suggest that the Handbook should give clearer
recommendations to ensure a more homogeneous meth-
odology.
Other problems with scales and items
Several groups recommended assessment of items in their
scales or checklists that are hardly related to the risk of
bias in clinical studies. For example, the Back Group and
the checklists of four other groups recommended to assess
for similarities between groups at baseline, but it is not
clear how or for what purpose. Proper randomisation
ensures that there is no selection bias, but it also means
that 5% of baseline characteristics will be expected to dif-
fer between the groups at the 5% significance level, and
1% at the 1% level, etc. Furthermore, significant differ-
ences in some characteristics may have no effect on the
outcome while non-significant differences in others may.
Statistical hypothesis testing of the distribution of base-
line characteristics should therefore usually only be per-
formed if fraud is suspected [28,29]. It can also be
problematic to assess the use of co-interventions and the
level of compliance, as both of these may merely reflect
the differential effects of the studied interventions.
Another example is the Moncrief scale that is used by the
Depression, Anxiety and Neurosis Group as a checklist,
without assigning an overall score as was originally the
intention [30]. This scale has 23 items and some relate to
external validity and appropriateness and reporting of sta-
tistical analysis, which are not associated with bias in the
study. As chance findings can be misinterpreted as bias,
such items can be problematic not only in a scale
approach but also in a component approach, if they are
used as a threshold for inclusion of studies in the review
or in a sensitivity analysis.
The Peripheral Vascular Diseases Group referred to the
"Schulz scale", but their reference includes no such scale
[4], and Schulz has never constructed one; in fact, he
advises against the use of scales for assessment of method-
ological quality. The Drugs and Alcohol Group recom-
mended against assessing detection bias because of low
interobserver agreement, but did not document this state-
ment. The Incontinence Group and the Heart Group
described attrition bias as selection bias occurring after
randomization, which, although not formally incorrect, is
confusing, as it is well understood that selection bias is
avoided by proper randomization.
The Musculoskeletal Group recommended a scale for
quality assessment of non-randomized studies [31]. The
problems with scales are likely much greater for non-ran-
domized studies than for randomized trials, as there is not
much empirical evidence for the degree of bias, on aver-
age, that is introduced if different criteria are not met.
Usage of methodological quality assessments
Only a little more than half of the groups had recommen-
dations for using the quality assessment in reviews. The
analytical method most often endorsed was sensitivity
analysis to test if including only trials of higher methodo-
logical quality changes the effect estimates. As explainedBMC Medical Research Methodology 2008, 8:22 http://www.biomedcentral.com/1471-2288/8/22
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above, such analyses should not be based on an overall
score. Rather than accepting the different combinations of
criteria that are possible using scales, one should use one
criterion, or only a few important ones simultaneously.
For example, in a Cochrane review where a main outcome
was number of blood transfusions [32], which is vulnera-
ble to bias if the trial is not blinded, high-quality trials
were defined as those that had adequate concealment of
allocation and double blinding. Furthermore, high- and
low-quality trials were grouped separately in the meta-
analyses for easy comparisons.
It is also questionable to exclude trials entirely from the
review if they fall below a certain quality cut-point on a
scale [24], whereas it can be entirely reasonable to include
only trials that are adequately randomized and blinded,
e.g. if the main outcome is subjective, such as pain.
Grading of the evidence for the whole review
Grading of the evidence can help guide the decisions of
clinicians and patients [33], provided the grading system
is logically consistent and is in accordance with results
from empirical studies. The grading system recommended
by the Back Group has five levels of evidence and was
developed using a consensus method [23]. Consistent
findings among multiple, low-quality non-randomized
studies are considered to be the same level of evidence as
one high-quality randomized trial, which is not in accord-
ance with findings from empirical studies [34,35], or with
the Cochrane Handbook [12]. Consistent results from
non-randomized studies may merely reflect that they are
all biased to a similar degree. This was the case, for exam-
ple, for hormone replacement therapy, where a meta-
analysis of observational studies [36] as well as a large
cohort study [37] showed that hormones decreased the
incidence of coronary heart disease by about 50%,
whereas a high-quality randomized trial showed that hor-
mones cause heart disease [38]. The Back Group intends
to remove this scale from its guidelines [39] and will use
the GRADE system for grading evidence [40,41].
The four-level grading system used by the Musculoskeletal
Group is also based on consensus [42] and is also highly
problematic. The system is based on arbitrary cut-points
such as sample size above 50 and more than 80% follow-
up, which are not based on empirical evidence. The only
difference between platinum and gold evidence is that
there needs to be two randomized trials for platinum and
one for gold, which is not reasonable, as, for example, the
platinum trials could involve 60 patients each and the
gold trial 500 patients. Silver level can be either a rand-
omized trial with a 'head-to-head' comparison of agents
or a high-quality case-control study, which is hard to
accept, and bronze level can be a high-quality case series
without controls or expert opinion.
Conclusions
The Cochrane Handbook is produced by experts in meth-
odology, is evidence-based, and is regularly updated in
accordance with new evidence. The long guidelines of
some review groups therefore seem to be superfluous, and
in some cases they are not in accordance with the Hand-
book, or with the empirical evidence on bias. As the
guidelines are probably followed by many review authors,
they could potentially threaten the credibility of the
reviews. We suggest that all Cochrane Review Groups refer
to the Cochrane Handbook in their instructions to
authors and that their own guidelines are kept to a mini-
mum and describe only how methodological topics that
are specific to their fields should be handled.
The Cochrane Handbook is currently being updated to
ensure a more homogenous methodology in its reviews
[43]. This revision is based on the acknowledgement of
the discrepancies in assessment of methodological quality
between the review groups [44], and it will involve intro-
duction of a detailed risk-of-bias tool to be used in all
reviews. The tool will also address bias in selective out-
come reporting [45,46]. Finally, we suggest that the revi-
sion should improve recommendations for assessing
attrition bias and the usage of the risk-of-bias assessments,
as the current recommendations are not clear about this.
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